NVO · Novo Nordisk
AI read · Good for NVO
The AI's read
The comparison with placebo gives Novo Nordisk evidence that CagriSema could add another option to its obesity-drug lineup. That may help its effort to remain competitive in obesity care. The drug is not approved yet, and the FDA decision is expected in the fourth quarter of 2026.